Logo image of TRVI

TREVI THERAPEUTICS INC (TRVI) Stock Fundamental Analysis

NASDAQ:TRVI - Nasdaq - US89532M1018 - Common Stock - Currency: USD

5.96  -0.11 (-1.81%)

After market: 5.96 0 (0%)

Fundamental Rating

3

TRVI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While TRVI has a great health rating, there are worries on its profitability. TRVI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRVI has reported negative net income.
In the past year TRVI has reported a negative cash flow from operations.
TRVI had negative earnings in each of the past 5 years.
In the past 5 years TRVI always reported negative operating cash flow.
TRVI Yearly Net Income VS EBIT VS OCF VS FCFTRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

TRVI has a Return On Assets of -42.99%. This is comparable to the rest of the industry: TRVI outperforms 44.10% of its industry peers.
TRVI has a Return On Equity of -46.46%. This is comparable to the rest of the industry: TRVI outperforms 54.36% of its industry peers.
Industry RankSector Rank
ROA -42.99%
ROE -46.46%
ROIC N/A
ROA(3y)-33.18%
ROA(5y)-51.45%
ROE(3y)-36.69%
ROE(5y)-85.71%
ROIC(3y)N/A
ROIC(5y)N/A
TRVI Yearly ROA, ROE, ROICTRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

TRVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRVI Yearly Profit, Operating, Gross MarginsTRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for TRVI has been increased compared to 1 year ago.
The number of shares outstanding for TRVI has been increased compared to 5 years ago.
TRVI has a better debt/assets ratio than last year.
TRVI Yearly Shares OutstandingTRVI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TRVI Yearly Total Debt VS Total AssetsTRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

TRVI has an Altman-Z score of 44.76. This indicates that TRVI is financially healthy and has little risk of bankruptcy at the moment.
TRVI's Altman-Z score of 44.76 is amongst the best of the industry. TRVI outperforms 96.92% of its industry peers.
TRVI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 44.76
ROIC/WACCN/A
WACCN/A
TRVI Yearly LT Debt VS Equity VS FCFTRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 15.43 indicates that TRVI has no problem at all paying its short term obligations.
The Current ratio of TRVI (15.43) is better than 87.69% of its industry peers.
TRVI has a Quick Ratio of 15.43. This indicates that TRVI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TRVI (15.43) is better than 87.69% of its industry peers.
Industry RankSector Rank
Current Ratio 15.43
Quick Ratio 15.43
TRVI Yearly Current Assets VS Current LiabilitesTRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

TRVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.35%.
EPS 1Y (TTM)-32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.41%
EPS Next 2Y-7.63%
EPS Next 3Y-14.17%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRVI Yearly Revenue VS EstimatesTRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B
TRVI Yearly EPS VS EstimatesTRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRVI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRVI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRVI Price Earnings VS Forward Price EarningsTRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRVI Per share dataTRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

TRVI's earnings are expected to decrease with -14.17% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.63%
EPS Next 3Y-14.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREVI THERAPEUTICS INC

NASDAQ:TRVI (6/20/2025, 8:01:24 PM)

After market: 5.96 0 (0%)

5.96

-0.11 (-1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06
Inst Owners66.07%
Inst Owner Change15.35%
Ins Owners13.68%
Ins Owner Change0.25%
Market Cap606.37M
Analysts86.67
Price Target21.08 (253.69%)
Short Float %9.45%
Short Ratio3.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.22%
Min EPS beat(2)9.29%
Max EPS beat(2)27.14%
EPS beat(4)2
Avg EPS beat(4)4.46%
Min EPS beat(4)-10.99%
Max EPS beat(4)27.14%
EPS beat(8)5
Avg EPS beat(8)5.43%
EPS beat(12)9
Avg EPS beat(12)12.13%
EPS beat(16)12
Avg EPS beat(16)11.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.2%
PT rev (3m)92.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.52%
EPS NY rev (1m)0%
EPS NY rev (3m)12.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.1
P/tB 6.1
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.99%
ROE -46.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.18%
ROA(5y)-51.45%
ROE(3y)-36.69%
ROE(5y)-85.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.43
Quick Ratio 15.43
Altman-Z 44.76
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)181.11%
Cap/Depr(5y)120.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y6.41%
EPS Next 2Y-7.63%
EPS Next 3Y-14.17%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.33%
EBIT Next 3Y-14.39%
EBIT Next 5Y-20.77%
FCF growth 1Y-39.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.98%
OCF growth 3YN/A
OCF growth 5YN/A